文献速递浆细胞疾病

TOURMALINE-MM1三期试验最终总生存分析:伊沙佐米联合来那度胺地塞米松治疗复发难治多发性骨髓瘤

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
PubMed 文献 · J Clin Oncol · 2021-06-11

TOURMALINE-MM1是一项双盲安慰剂对照三期试验,比较伊沙佐米联合来那度胺地塞米松(IRd)与安慰剂Rd在复发难治多发性骨髓瘤中的疗效。

要点

  • 在不良预后亚组(如高危细胞遗传学、ISS III期)中IRd的OS获益更明显。
  • 后续治疗不平衡(尤其蛋白酶体抑制剂和达雷妥尤单抗)可能混淆OS解读。

核心结论

  • 不良预后亚组中IRd的OS获益幅度更大。
  • 后续治疗(尤其PIs和达雷妥尤单抗)的不平衡可能混淆OS解读。

研究设计与样本

  • 双盲、安慰剂对照、三期TOURMALINE-MM1研究。
  • 患者随机分配至IRd组(n=360)或安慰剂Rd组(n=362),按既往治疗线数、既往PI暴露和ISS分期分层。
  • OS为意向治疗人群的关键次要终点。

主要发现

  • 预设亚组HR:对任何治疗线难治0.794,对末线难治0.742,年龄>65-75岁0.757,ISS III期0.779,既往2/3线治疗0.845,高危细胞遗传学0.870,高危细胞遗传学和/或1q21扩增0.862。
  • IRd组与安慰剂Rd组分别有71.7%与69.9%患者接受≥1种抗癌治疗,其中接受达雷妥尤单抗者24.7% vs 33.9%,接受PIs者71.8% vs 76.9%,下一线治疗者47.5% vs 55.8%。
  • 新原发恶性肿瘤发生率IRd组10.3%,安慰剂Rd组11.9%。
  • 未发现新的或额外的安全性问题。

关键数值与推荐

  • 预设亚组OS HR:对任何治疗线难治0.794,对末线难治0.742,年龄>65-75岁0.757,ISS III期0.779,既往2/3线治疗0.845,高危细胞遗传学0.870,高危细胞遗传学和/或1q21扩增0.862。
  • 后续治疗比例:IRd组71.7% vs 安慰剂Rd组69.9%接受≥1种抗癌治疗;达雷妥尤单抗24.7% vs 33.9%;PIs 71.8% vs 76.9%;下一线治疗47.5% vs 55.8%。
  • 新原发恶性肿瘤:IRd组10.3%,安慰剂Rd组11.9%。

临床怎么用

  • IRd方案在复发难治多发性骨髓瘤中未显示显著OS获益,但PFS获益明确。
  • 对于具有不良预后因素(如高危细胞遗传学、ISS III期、早期复发)的患者,IRd可能提供更大的OS获益。
  • 解读OS时需考虑后续治疗的可及性和不平衡。

局限性

  • OS分析受后续治疗不平衡(尤其PIs和达雷妥尤单抗)混淆。
  • 亚组分析为探索性,需谨慎解读。
  • 中位随访85个月,但后续治疗影响OS评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd in patients with relapsed or refractory multiple myeloma. We report the final analyses for overall survival (OS). PATIENTS AND METHODS: Patients were randomly assigned to ixazomib-Rd (n = 360) or placebo-Rd (n = 362), stratified by number of prior therapies (1 v 2 or 3), previous proteasome inhibitor (PI) exposure (yes v no), and International Staging System disease stage (I or II v III). OS (intent-to-treat population) was a key secondary end point. RESULTS: With a median follow-up of 85 months, median OS with ixazomib-Rd versus placebo-Rd was 53.6 versus 51.6 months (hazard ratio, 0.939; P = .495). Lower hazard ratios, indicating larger magnitude of OS benefit with ixazomib-Rd versus placebo-Rd, were seen in predefined subgroups: refractory to any (0.794) or last (0.742) treatment line; age > 65-75 years (0.757); International Staging System stage III (0.779); 2/3 prior therapies (0.845); high-risk cytogenetics (0.870); and high-risk cytogenetics and/or 1q21 amplification (0.862). Following ixazomib-Rd versus placebo-Rd, 71.7% versus 69.9% of patients received ≥ 1 anticancer therapy, of whom 24.7% versus 33.9% received daratumumab and 71.8% versus 76.9% received PIs (next-line therapy: 47.5% v 55.8%). Rates of new primary malignancies were similar with ixazomib-Rd (10.3%) and placebo-Rd (11.9%). There were no new or additional safety concerns. CONCLUSION: Median OS values in both arms were the longest reported in phase III studies of Rd-based triplets in relapsed or refractory multiple myeloma at the time of this analysis; progression-free survival benefit with ixazomib-Rd versus placebo-Rd did not translate into a statistically significant OS benefit on intent-to-treat analysis. OS benefit was greater in subgroups with adverse prognostic factors. OS interpretation was confounded by imbalances in subsequent therapies received, especially PIs and daratumumab.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Richardson PG, Kumar SK, Masszi T, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021. PMID: 34111952. doi:10.1200/JCO.21.00972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。